1 IARC Working Group on the Evaluation of Cancer Preventive Strategies. IARC handbooks of cancer prevention, Volume 10: Cervix cancer screening. Lyon: IARC Press, 2005.
2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
3 Nicer.org [Internet]. NICER-National Institute for Cancer Epidemiology and Registration. Zitiert am 29.1.2019. Erhältlich über:
http://www.nicer.org/NicerReportFiles2018/DE/report/atlas.html?&geog=1.
4 Zwahlen M. Nationales Krebsprogramm für die Schweiz 2011–2015 – Früherkennung. [Internet]. Zitiert am 29.1.2019. Erhältlich über:
https://www.nsk-krebsstrategie.ch/wp-content/uploads/2015/08/nkp_2011_2015_dt.pdf.
5 Marquardt K, Büttner HH, Broschewitz U, Barten M, Schneider V. Persistent Carcinoma in Cervical Cancer Screening: Non-Participation Is the Most Significant Cause. Acta Cytologica. 2011;55:433–7.
6 Mathias JS, Gossett D, Baker DW. Use of electronic health record data to evaluate overuse of cervical cancer screening. Am Med Inform Assoc. 2012;19(e1):e96–e101.
7 Weinmann S, Naleway A, Swamy G, Krishnarajah G, Arondekar B, Fernandez J, et al. Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study. PLoS ONE. 2017;12(1):e0165276.
8 Melnikow J, T Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing. Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(7):687–705.
9 Ronco G, Dillner J, Elfström MM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):62218–7.
10 Sideri M, Igidbashian S. HPV-based screening for prevention of invasive cervical. Lancet. 2014;383(9925):60634–7.
11 Hopenhayn C, Christian A, Christian WJ, Watson M, Unger ER, Lynch CF, et al. Prevalence of human papillomavirus types in invasive cervical cancers from seven US cancer registries prior to vaccine introduction. J Low Genit Tract Dis. 2014;18(2):182–9.
12 Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864–7.
13 Elfström KM, Smelov V, Johansson ALV, Eklund CE, Nauclér P, Arnheim-Dahlström L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;16;348:g130.
14 Curry, SJ. Screening for Cervical Cancer US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674–86.
15 Frey Tirry B, Petignat P, Jacot-Guillarmod M, Mueller MD, Mathias Fehr M, Kind AB. Empfehlungen für die Gebärmutterhalskrebsvorsorge. Expertenbrief No 50. SGGG. [Internet] 1.3.2018. Zitiert am 29.1.2019. Erhältlich über:
https://www.sggg.ch/fileadmin/user_upload/Formulardaten/akt_50_D_Gebaermutterhalskrebsvorsorge_01.03.18.pdf.
16 von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research. 2015;1:22–31.
17 Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol. 2014;210(5):474e1–7.
18 WHO: Screening for various cancers [Internet]. Erhältlich über: https://www.who.int/cancer/detection/variouscancer/en/. WHO: Screening for various cancers. Zitiert am 29.1.2019.
19 Viviano M, Catarino R, Jeannot E, Boulvain M, Malinverno MU, Vassilakos P, et al. Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. Br J Cancer. 2017;116:1382–8.